MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 414317 | Name: Nemonoxacin Free Base

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nemonoxacin Free Base has antibacterial activity.

Chemical Structure

Nemonoxacin Free Base
Nemonoxacin Free Base
CAS#378746-64-6 (free base)

Theoretical Analysis

MedKoo Cat#: 414317

Name: Nemonoxacin Free Base

CAS#: 378746-64-6 (free base)

Chemical Formula: C20H25N3O4

Exact Mass: 371.1845

Molecular Weight: 371.44

Elemental Analysis: C, 64.67; H, 6.78; N, 11.31; O, 17.23

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
378746-64-6 (free base) 951163-60-3 (malate) 951313-26-1 (malate hemihydrate)
Synonym
Nemonoxacin Free Base; TG873870; TG-873870; TG 873870
IUPAC/Chemical Name
7-((3S,5S)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
InChi Key
AVPQPGFLVZTJOR-RYUDHWBXSA-N
InChi Code
InChI=1S/C20H25N3O4/c1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26/h5-6,10-13H,3-4,7-9,21H2,1-2H3,(H,25,26)/t11-,12-/m0/s1
SMILES Code
COc1c2c(C(C(C(O)=O)=CN2C3CC3)=O)ccc1N4C[C@H](C[C@@H](C4)N)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 371.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Yuan J, Mo B, Ma Z, Lv Y, Cheng SL, Yang Y, Tong Z, Wu R, Sun S, Cao Z, Wu J, Zhu D, Chang L, Zhang Y; Investigator Group of the Phase 3 Study on Oral Nemonoxacin. Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. J Microbiol Immunol Infect. 2019 Feb;52(1):35-44. doi: 10.1016/j.jmii.2017.07.011. Epub 2017 Aug 2. PMID: 30181096. 2: Chen N, Li X, Guo B, Zou J, Lin D, Li X, Huang J, Feng M, Zhao X. Nemonoxacin Has Immunoprotective Effects on Reducing Mortality in Lipopolysaccharide-Induced Mouse Sepsis Model. Inflammation. 2020 Dec;43(6):2276-2286. doi: 10.1007/s10753-020-01296-9. PMID: 32661821. 3: Huang CH, Lai CC, Chen YH, Hsueh PR. The potential role of nemonoxacin for treatment of common infections. Expert Opin Pharmacother. 2015 Feb;16(2):263-70. doi: 10.1517/14656566.2015.978288. Epub 2014 Dec 22. PMID: 25529577. 4: Poole RM. Nemonoxacin: first global approval. Drugs. 2014 Aug;74(12):1445-53. doi: 10.1007/s40265-014-0270-0. PMID: 25079302. 5: Qin X, Huang H. Review of nemonoxacin with special focus on clinical development. Drug Des Devel Ther. 2014 Jul 5;8:765-74. doi: 10.2147/DDDT.S63581. PMID: 25045247; PMCID: PMC4094567. 6: Kang Y, Li Y, Xu F, Zhang J, Wang K, Chen Y, Wu J, Guo B, Yu J, Zhang Y. Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment. Clin Ther. 2019 Mar;41(3):505-517.e0. doi: 10.1016/j.clinthera.2019.01.015. Epub 2019 Feb 26. PMID: 30819510. 7: Yang JJ, Cheng A, Tai HM, Chang LW, Hsu MC, Sheng WH. Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan. Microb Drug Resist. 2020 Feb;26(2):110-117. doi: 10.1089/mdr.2019.0048. Epub 2019 Aug 30. PMID: 31478786. 8: Wang N, Liu W, Zhou Y, Liu Y. In vitro Activities of Nemonoxacin and Other Antimicrobial Agents Against Human Mycoplasma and Ureaplasmas Isolates and Their Defined Resistance Mechanisms. Front Microbiol. 2019 Aug 13;10:1890. doi: 10.3389/fmicb.2019.01890. PMID: 31456791; PMCID: PMC6700270. 9: Zhao C, Lv Y, Li X, Hou F, Ma X, Wei M, Kang Z, Cui L, Xia Y, Liu Y, Tian J. Effects of Nemonoxacin on Thorough ECG QT/QTc Interval: A Randomized, Placebo- and Positive-controlled Crossover Study in Healthy Chinese Adults. Clin Ther. 2018 Jun;40(6):983-992. doi: 10.1016/j.clinthera.2018.04.014. Epub 2018 May 24. PMID: 29803534. 10: Zhao B, Yu X, Chen R, Zheng R. Efficacy and Safety of Nemonoxacin in Outpatients with Community-Acquired Pneumonia. Infect Drug Resist. 2020 Jul 2;13:2099-2104. doi: 10.2147/IDR.S248092. PMID: 32669862; PMCID: PMC7337426.

View History

Nematolin

Nematolin